Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Clinical Pharmacology and Therapeutics
|
April 1, 2018
Understanding Hematological Toxicities Using Mathematical Modeling
Chiara Fornari, Lenka Oplustil O'Connor, James W T Yates, et al.
Communications Biology
|
August 25, 2021
Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response
Tudor Petreus, Elaine Cadogan, Gareth Hughes, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 12, 2019
Quantifying Drug-Induced Bone Marrow Toxicity Using a Novel Haematopoiesis Systems Pharmacology Model
Chiara Fornari, Lenka Oplustil O'Connor, Carmen Pin, et al.
Scientific Reports
|
March 1, 2026
Micronucleus quantification from whole-slide haematology images using AI serves as a translatable pharmacodynamic biomarker for DNA damage response inhibitors
Killian H R Yong, Weronika S Robak, Lee Mulderrig, et al.
Nature Communications
|
October 28, 2025
Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling
Anish Thomas, Nobuyuki Takahashi, Lenka Oplustil O'Connor, et al.
Cancer Research
|
May 25, 2019
Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress
Lucy A Young, Lenka Oplustil O'Connor, Christelle de Renty, et al.
British Journal of Cancer
|
May 17, 2025
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study
Timothy A Yap, Patricia LoRusso, Rowan E Miller, et al.
Cancer Research
|
August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Lenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Joyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
Nature Communications
|
November 9, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
Jacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Clinical Pharmacology and Therapeutics
|
April 1, 2018
Understanding Hematological Toxicities Using Mathematical Modeling
Chiara Fornari, Lenka Oplustil O'Connor, James W T Yates, et al.
Communications Biology
|
August 25, 2021
Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response
Tudor Petreus, Elaine Cadogan, Gareth Hughes, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 12, 2019
Quantifying Drug-Induced Bone Marrow Toxicity Using a Novel Haematopoiesis Systems Pharmacology Model
Chiara Fornari, Lenka Oplustil O'Connor, Carmen Pin, et al.
Scientific Reports
|
March 1, 2026
Micronucleus quantification from whole-slide haematology images using AI serves as a translatable pharmacodynamic biomarker for DNA damage response inhibitors
Killian H R Yong, Weronika S Robak, Lee Mulderrig, et al.
Nature Communications
|
October 28, 2025
Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling
Anish Thomas, Nobuyuki Takahashi, Lenka Oplustil O'Connor, et al.
Cancer Research
|
May 25, 2019
Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress
Lucy A Young, Lenka Oplustil O'Connor, Christelle de Renty, et al.
British Journal of Cancer
|
May 17, 2025
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study
Timothy A Yap, Patricia LoRusso, Rowan E Miller, et al.
Cancer Research
|
August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Lenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Joyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
Nature Communications
|
November 9, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
Jacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, et al.
Page
of 2